34 hasil untuk "Francesco Loconsole"
Menampilkan 1–20 · 0,38 detik · RSS
-
Artikel Jurnal
Upadacitinib for the management of refractory hidradenitis suppurativa, psoriasis, and pyoderma gangrenosum
Dear Editor, Hidradenitis suppurativa (HS) is a chronic immune-mediated skin disease presenting with recurrent inflammatory nodules, abscesses, draining tunnels, and scarring, most commonly in intertriginous sites. Its estimated global prevalence is approximately 1% and its pathogenesis is complex…
-
Artikel Jurnal
Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy
Purpose: The objective of this analysis was to compare the cost per responder between risankizumab and secukinumab among patients with moderate-to-severe plaque psoriasis in Italy. Methods: The clinical efficacy was assessed based on IMMerge study of published efficacy data as measured by Psoriasis…
-
Artikel Jurnal
Therapeutic outcomes of CAL/BDP PAD‑based cream in patients with mild-to-moderate psoriasis: insights from four case reports
Topical medications are commonly used to manage mild‑to‑moderate psoriasis as adjunctive treatments in patients receiving phototherapy, systemic agents or biologic therapies. Amongst available topical options, the fixed-dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP) has…
-
Artikel Jurnal
Cost analysis in the management of moderate-to-severe psoriasis: comparison between conventional and biological systemic therapies
Background. Psoriasis is a chronic inflammatory skin disease with an important socio-economic burden. Available therapies include conventional systemic drugs and biological drugs, such as Tumor Necrosis Factor (TNF)-α inhibitors, that are characterized by high costs. Aim. Perform a cost-estimation…
-
Artikel Jurnal
Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-α therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion to positive TBC status among patients with…
-
Artikel Jurnal
Toward the definition of moderate psoriasis: an expert opinion
Background The clinical definition of moderate psoriasis is debated, affecting treatment eligibility and patient outcomes.Objective A panel of Italian dermatologists aimed to propose practical criteria to define moderate psoriasis, based on a comprehensive literature review and clinical…
-
Artikel Jurnal
OPT-In; Optimized Patient Treatment Outcomes in Plaque Psoriasis: A 3-Year State-Transition Treatment-Sequencing Model in the Italian Setting
Abstract Introduction There are several treatment options for plaque psoriasis (PsO), but uncertainty remains around the optimal sequencing of treatments. The aims of this study were to investigate how adopting a best-treatment-first treatment sequence impacts patient outcomes and healthcare…
-
Artikel Jurnal
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis)
Background: Interleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use in patients with a history of cancer is debated.Objective: We conducted a multicenter retrospective study across nine Italian Dermatology Units to assess the…
-
Artikel Jurnal
Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy
Background Long-term real-life data on secukinumab use in psoriasis are limited. Objectives Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in real-life. Methods Multicenter retrospective study analyzing data from adult patients treated with secukinumab for at…
-
Artikel Jurnal
Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi Consensus
Abstract Background After decades of use, methotrexate displays an established safety and efficacy profile in both in-hospital and outpatient settings. Despite its widespread use, there is surprisingly little clinical evidence to guide daily practice with methotrexate in dermatology. Objectives To…
-
Artikel Jurnal
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study
This study evaluated whether secukinumab treatment for patients with moderate to severe plaque psoriasis correlates with improvements in symptoms of anxiety and depression. SUPREME was a 24-week, phase IIIb, multicentre, prospective study conducted across 50 centres in Italy with an extension…
-
Artikel Jurnal
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)
Abstract Introduction The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safety in both clinical trials and real-world…
-
Artikel Jurnal
Effectiveness of tildrakizumab 200 mg: an Italian multicenter study
Introduction: Psoriasis is a chronic immune-mediated disease that can be challenging to treat, especially in patients with severe disease or high body weight. Tildrakizumab is a monoclonal antibody which inhibits IL-23, approved for moderate-to-severe psoriasis with a standard 100 mg dose. A 200 mg…
-
Artikel Jurnal
GRINCH Index: Measuring Patient Satisfaction During Christmas Holiday Gift Programs
Introduction: Receiving gifts, especially during the Christmas festivities, is a common experience for healthcare providers. Gift-giving, being a spontaneous expression of gratitude, could enable the assessment of true patient satisfaction. Objective: In this study we used the Gifts Received durINg…
-
Artikel Jurnal
Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis
Abstract Introduction Moderate psoriasis, despite its clinical relevance, remains inconsistently defined in current guidelines, leading to heterogeneous treatment decisions and variable access to systemic therapy. A unified, clinically meaningful definition is currently lacking. To establish a…
-
Artikel Jurnal
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study
Abstract Introduction Psoriasis is a chronic inflammatory skin disorder, affecting around 2–3% of the global population. The IL-23/Th17 signaling pathway plays a critical role in disease progression. Guselkumab, an IL-23p19 monoclonal antibody, has shown substantial efficacy in clinical trials for…
-
Artikel Jurnal
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
IntroductionBrodalumab is a monoclonal antibody that targets the subunit A of the interleukin-17A receptor (IL17RA), inhibiting the signaling of various isoforms of the IL-17 family. It has been approved for the treatment of moderate-to-severe plaque psoriasis after being evaluated in three Phase-3…
-
Artikel Jurnal
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis)
IntroductionThe development of several effective biological drugs for moderate-to-severe plaque psoriasis has dramatically changed the lives of patients. Despite the wide use of interleukin (IL) inhibitors, limited data are available to date regarding long-term treatment persistence.MethodThis…
-
Artikel Jurnal
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study
Abstract Introduction Secukinumab, approved in 2015 for the treatment of moderate-to-severe psoriasis, has demonstrated sustained efficacy and safety in pivotal randomized controlled trials. However, real-world data on its long-term effectiveness and safety are limited. We conducted a multicenter…